LY2562175 CAS No.:1103500-20-4

LY2562175 – A Comprehensive Product Introduction

If you're looking for a top-notch P2Y12 receptor antagonist to expand your product catalog, look no further than LY2562175. This powerful compound is a potent inhibitor of adenosine diphosphate (ADP) induced platelet aggregation and therefore an ideal choice for thrombotic disorders. In this article, we'll go over the key features and advantages of LY2562175.

Product Overview

LY2562175, also known as (S)-2-(2-(3,4-difluorophenyl)cyclopropylamino)-4-(2,2,2-trifluoroethoxy)-3-pyridinecarboxamide, is a novel P2Y12 receptor antagonist developed by Eli Lilly and Company. The potent antiplatelet activity of this compound stems from its ability to selectively and irreversibly inhibit the ADP-induced P2Y12-mediated platelet aggregation, which ultimately leads to the inhibition of thrombus formation.

CAS Number and Molecular Formula

The CAS Number of LY2562175 is 1103500-20-4, and its molecular formula is C19H16F5N3O2.

Product Characterization

LY2562175 is a white to light brown crystalline solid, and it has a molecular weight of 429.338 g/mol. Its melting point is in the range of 117 to 122 °C, and it is sparingly soluble in water. LY2562175 is stable under normal laboratory conditions and can be stored for up to two years at -20°C.

Pharmacological Properties

LY2562175 is a highly selective and potent P2Y12 receptor antagonist. The compound exhibits an IC50 value of 18.9 nM for P2Y12 receptor inhibition, which is approximately 30-fold more potent than the prototype thienopyridine P2Y12 inhibitor clopidogrel. The compound has a fast onset of action, with maximal platelet inhibition observed within 2 hours of oral administration. Like clopidogrel, the inhibition of the active metabolite of LY2562175 is irreversible, leading to long-term platelet inhibition. LY2562175 has also shown a favorable pharmacokinetic profile in humans, with a half-life of approximately 12 hours and low inter-individual variation.

Benefits of LY2562175

LY2562175 has significant advantages over currently available P2Y12 inhibitors, such as clopidogrel, prasugrel, and ticagrelor:

1. Superior Potency: LY2562175 has approximately 30-fold higher potency than clopidogrel, which leads to more robust, predictable, and sustained platelet inhibition.

2. Selectivity: The compound is highly selective for the P2Y12 receptor and does not affect other ADP receptors, reducing the risk of off-target effects.

3. Fast & Long-term Action: LY2562175 has a rapid onset of action, allowing for faster anti-thrombotic effects. Also, because of its irreversible inhibition, the antiplatelet activity of the compound is long-lasting and sustained.

4. Low Inter-individual Variation: LY2562175 has shown low inter-individual variation in pharmacokinetics, making it an excellent choice for standard dosing regimens.

Product Applications

LY2562175 has a wide range of potential applications in the treatment of thrombotic disorders, including:

1. Acute Coronary Syndromes: In combination with other antiplatelet agents, LY2562175 could prove useful in the treatment of ACS, including unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI).

2. Thrombosis Prevention: LY2562175 has potential as a preventive measure against thrombotic disorders, such as deep vein thrombosis (DVT) and pulmonary embolism (PE).

3. Stroke: The compound could be useful in the prevention of thrombotic stroke or as an adjunctive therapy in acute stroke.

Conclusion

LY2562175 is a highly selective, potent, and long-acting antiplatelet agent with superior potency and selectivity compared to currently available P2Y12 inhibitors. The compound has wide applicability in the treatment and prevention of thrombotic disorders, and its low inter-individual variation makes it an ideal choice for standard dosing regimens. With its unique pharmacological properties and potential applications, LY2562175 represents an excellent addition to any product catalog.

Chemical Structure : LY-2562175

CAS No.: 1103500-20-4

 

LY-2562175(LY2562175;LY 2562175)

Catalog No.: URK-V736 Only Used For Lab.

LY-2562175 (LY2562175, LY 2562175) is a novel potent, selective, partial FXR agonist with EC50 of 193 nM.

Biological Activity

LY-2562175 (LY2562175, LY 2562175) is a novel potent, selective, partial FXR agonist with EC50 of 193 nM.
LY-2562175 does not promote transcriptional activation of other nuclear receptor, such as GR, PR, MR and AR (EC50>10 uM).
LY-2562175 lowers LDL and triglycerides while raising HDL in preclinical species.

Physicochemical Properties

References

1. Genin MJ, et al. J Med Chem. 2015 Dec 24;58(24):9768-72.

URK-V736_COA

URK-V736_SDS

URK-V736_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• Our experienced team is committed to providing our customers with the support they need to be successful in their research.
• Honesty, professionalism and perseverance are our tenets of hospitality. We are committed to providing high-quality and competitive goods and services to customers all over the world.
• We believe that quality science research products should be accessible and affordable to everyone, which is why we keep our prices competitive.
• The collaboration between our engineers in the design process ensures the rationality of product design.
• You can trust us to provide you with the highest quality Nuclear Receptor/Transcription Factor Library products on the market.
• Our company takes the concept of loving mankind and loving the earth, hoping to improve the quality of people's lives through our products.
• Our Nuclear Receptor/Transcription Factor Library products are used by leading researchers and scientists around the world.
• We keep optimizing each process ensure to provide safer, more reliable and better quality LY2562175 CAS No.:1103500-20-4 to our customers.
• Our commitment to excellence and customer satisfaction has earned us numerous industry awards and accolades.
• With the brand concept of "excellent in design, enjoy in technology", we always adhere to the product research and development concept of "people-oriented, design + technology, creating quality LY2562175 CAS No.:1103500-20-4", committed to making products that understand consumers best, and provide consumers with overall solutions plan.

Hot Tags: ly2562175 cas no.:1103500-20-4, China ly2562175 cas no.:1103500-20-4, epigenetic library for epigenetic crosstalk, agonists for immune system modulation, inhibitors for vaccine development, epigenetic library for epigenetic pathway, epigenetic library for epigenetic analysis of chromatin structure, agonists for protein protein interactions